BPC-157

Peptide

BPC-157 (also known as PL 14736) is an oligopeptide consisting of a chain of fifteen amino acids. It has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.[1] This peptide has a molecular formula of C62H98N16O22. As of 2022, the peptide is banned by the World Anti-Doping Agency under the S0 category of non-exempt substances.[2]

Preclinical studies and limited clinical trials have indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may accelerate tissue healing.[3][4][5][6]

Research

There are some tentative pre-clinical studies on animals and in vitro suggesting possible benefit in wound healing and bowel disorders although all of these studies come from a single research group.[7][8]

Unapproved marketing

BPC 157 is marketed in functional medicine, although, FDA approval is not issued yet for it to be used in standard medicine.[9]

References

  1. ^ Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. (August 1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379 (1): 19–31. doi:10.1016/S0014-2999(99)00486-0. PMID 10499368.
  2. ^ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" (PDF). World Anti-Doping Agency. WADA. Retrieved 21 February 2022.
  3. ^ Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, et al. (March 2022). "Pentadecapeptide BPC 157 and the central nervous system". Neural Regeneration Research. 17 (3): 482–487. doi:10.4103/1673-5374.320969. PMC 8504390. PMID 34380875.
  4. ^ Chang C, Tsai W, Lin M, Hsu Y, Pang JS (October 28, 2010). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology. 110 (3): 774–780. doi:10.1152/japplphysiol.00945.2010. PMID 21030672.
  5. ^ Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth". Journal of Orthopaedic Research. 21 (6): 976–983. doi:10.1016/S0736-0266(03)00110-4. PMID 14554208.
  6. ^ Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2011). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract". Current Pharmaceutical Design. 17 (16): 1612–32. doi:10.2174/138161211796196954. PMID 21548867.
  7. ^ Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. (December 2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology. 14 (5–6): 214–221. doi:10.1007/s10787-006-1531-7. PMID 17186181. S2CID 24132425.
  8. ^ Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. PMID 20225319. S2CID 22085833.
  9. ^ Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. (2016). "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications". Current Neuropharmacology. 14 (8): 857–865. doi:10.2174/1570159x13666160502153022. PMC 5333585. PMID 27138887.